APO Research
Talk to an analyst

APO RESEARCH · REPORT

PARP Inhibitors for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PARP Inhibitors for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026184 pages

Choose your research edition.

Industry ResearchPARP Inhibitors for Cancer Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal PARP Inhibitors for Cancer Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal PARP Inhibitors for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PARP Inhibitors for Cancer Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal PARP Inhibitors for Cancer Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global PARP Inhibitors for Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for PARP Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PARP Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PARP Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PARP Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PARP Inhibitors for Cancer include Merck & Co, Pfizer, AstraZeneca, Tesaro and Clovis Oncology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PARP Inhibitors for Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PARP Inhibitors for Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PARP Inhibitors for Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PARP Inhibitors for Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.

PARP Inhibitors for Cancer Segment by Company

Merck & Co

Pfizer

AstraZeneca

Tesaro

Clovis Oncology

PARP Inhibitors for Cancer Segment by Type

Lynparza

Rubraca

Zejula

Talzenna

Other

PARP Inhibitors for Cancer Segment by Application

Ovarian Cancer

Breast Cancer

Other

PARP Inhibitors for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PARP Inhibitors for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PARP Inhibitors for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PARP Inhibitors for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PARP Inhibitors for Cancer market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PARP Inhibitors for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PARP Inhibitors for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PARP Inhibitors for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PARP Inhibitors for Cancer Industry Trends Table 2. PARP Inhibitors for Cancer Industry Drivers Table 3. PARP Inhibitors for Cancer Industry Opportunities and Challenges Table 4. PARP Inhibitors for Cancer Industry Restraints Table 5. Global PARP Inhibitors for Cancer Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PARP Inhibitors for Cancer Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PARP Inhibitors for Cancer Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global PARP Inhibitors for Cancer Sales Market Share by Manufacturers Table 9. Global PARP Inhibitors for Cancer Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global PARP Inhibitors for Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PARP Inhibitors for Cancer Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PARP Inhibitors for Cancer Manufacturers, Product Type & Application Table 13. Global PARP Inhibitors for Cancer Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PARP Inhibitors for Cancer by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lynparza Table 17. Major Manufacturers of Rubraca Table 18. Major Manufacturers of Zejula Table 19. Major Manufacturers of Talzenna Table 20. Major Manufacturers of Other Table 21. Global PARP Inhibitors for Cancer Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global PARP Inhibitors for Cancer Sales by Type (2021-2026) & (K Units) Table 23. Global PARP Inhibitors for Cancer Sales by Type (2027-2032) & (K Units) Table 24. Global PARP Inhibitors for Cancer Sales Market Share by Type (2021-2026) Table 25. Global PARP Inhibitors for Cancer Sales Market Share by Type (2027-2032) Table 26. Global PARP Inhibitors for Cancer Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global PARP Inhibitors for Cancer Revenue by Type (2021-2026) & (K Units) Table 28. Global PARP Inhibitors for Cancer Revenue by Type (2027-2032) & (K Units) Table 29. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2021-2026) Table 30. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Ovarian Cancer Table 32. Major Manufacturers of Breast Cancer Table 33. Major Manufacturers of Other Table 34. Global PARP Inhibitors for Cancer Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global PARP Inhibitors for Cancer Sales by Application (2021-2026) & (K Units) Table 36. Global PARP Inhibitors for Cancer Sales by Application (2027-2032) & (K Units) Table 37. Global PARP Inhibitors for Cancer Sales Market Share by Application (2021-2026) Table 38. Global PARP Inhibitors for Cancer Sales Market Share by Application (2027-2032) Table 39. Global PARP Inhibitors for Cancer Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global PARP Inhibitors for Cancer Revenue by Application (2021-2026) & (K Units) Table 41. Global PARP Inhibitors for Cancer Revenue by Application (2027-2032) & (K Units) Table 42. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2021-2026) Table 43. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2027-2032) Table 44. Global PARP Inhibitors for Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global PARP Inhibitors for Cancer Sales by Region (2021-2026) & (K Units) Table 46. Global PARP Inhibitors for Cancer Sales Market Share by Region (2021-2026) Table 47. Global PARP Inhibitors for Cancer Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global PARP Inhibitors for Cancer Sales Forecasted Market Share by Region (2027-2032) Table 49. North America PARP Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America PARP Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 51. North America PARP Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 52. Europe PARP Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe PARP Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 54. Europe PARP Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific PARP Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific PARP Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific PARP Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa PARP Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa PARP Inhibitors for Cancer Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa PARP Inhibitors for Cancer Sales by Country (2027-2032) & (K Units) Table 61. Global PARP Inhibitors for Cancer Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global PARP Inhibitors for Cancer Revenue by Region (2021-2026) & (US$ Million) Table 63. Global PARP Inhibitors for Cancer Revenue by Region (2027-2032) & (US$ Million) Table 64. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2021-2026) Table 65. Global PARP Inhibitors for Cancer Revenue Market Share by Region (2027-2032) Table 66. Merck & Co Company Information Table 67. Merck & Co Business Overview Table 68. Merck & Co PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Merck & Co PARP Inhibitors for Cancer Product Portfolio Table 70. Merck & Co Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Pfizer PARP Inhibitors for Cancer Product Portfolio Table 75. Pfizer Recent Development Table 76. AstraZeneca Company Information Table 77. AstraZeneca Business Overview Table 78. AstraZeneca PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. AstraZeneca PARP Inhibitors for Cancer Product Portfolio Table 80. AstraZeneca Recent Development Table 81. Tesaro Company Information Table 82. Tesaro Business Overview Table 83. Tesaro PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Tesaro PARP Inhibitors for Cancer Product Portfolio Table 85. Tesaro Recent Development Table 86. Clovis Oncology Company Information Table 87. Clovis Oncology Business Overview Table 88. Clovis Oncology PARP Inhibitors for Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Clovis Oncology PARP Inhibitors for Cancer Product Portfolio Table 90. Clovis Oncology Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. PARP Inhibitors for Cancer Distributors List Table 94. PARP Inhibitors for Cancer Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. PARP Inhibitors for Cancer Product Image Figure 2. Global PARP Inhibitors for Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PARP Inhibitors for Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global PARP Inhibitors for Cancer Sales (2021-2032) & (K Units) Figure 5. Global PARP Inhibitors for Cancer Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 PARP Inhibitors for Cancer Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lynparza Image Figure 9. Rubraca Image Figure 10. Zejula Image Figure 11. Talzenna Image Figure 12. Other Image Figure 13. Global PARP Inhibitors for Cancer Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global PARP Inhibitors for Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global PARP Inhibitors for Cancer Sales Market Share by Type (2021-2032) Figure 16. Global PARP Inhibitors for Cancer Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global PARP Inhibitors for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global PARP Inhibitors for Cancer Revenue Market Share by Type (2021-2032) Figure 19. Ovarian Cancer Image Figure 20. Breast Cancer Image Figure 21. Other Image Figure 22. Global PARP Inhibitors for Cancer Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global PARP Inhibitors for Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global PARP Inhibitors for Cancer Sales Market Share by Application (2021-2032) Figure 25. Global PARP Inhibitors for Cancer Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global PARP Inhibitors for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global PARP Inhibitors for Cancer Revenue Market Share by Application (2021-2032) Figure 28. North America PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America PARP Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 30. U.S. PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe PARP Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 35. Germany PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific PARP Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 42. China PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa PARP Inhibitors for Cancer Sales Market Share by Country (2021-2032) Figure 50. Brazil PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile PARP Inhibitors for Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global PARP Inhibitors for Cancer Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global PARP Inhibitors for Cancer Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America PARP Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 61. North America PARP Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe PARP Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 63. Europe PARP Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific PARP Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific PARP Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa PARP Inhibitors for Cancer Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa PARP Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. PARP Inhibitors for Cancer Value Chain Figure 69. Manufacturing Cost Structure Figure 70. PARP Inhibitors for Cancer Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Lynparza
  • Rubraca
  • Zejula
  • Talzenna
  • Other
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Other
Companies covered
  • Merck & Co
  • Pfizer
  • AstraZeneca
  • Tesaro
  • Clovis Oncology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PARP Inhibitors for Cancer Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PARP Inhibitors for Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PARP Inhibitors for Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PARP Inhibitors for Cancer Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PARP Inhibitors for Cancer Market Dynamics
  1. 2.1 PARP Inhibitors for Cancer Industry Trends
  2. 2.2 PARP Inhibitors for Cancer Industry Drivers
  3. 2.3 PARP Inhibitors for Cancer Industry Opportunities and Challenges
  4. 2.4 PARP Inhibitors for Cancer Industry Restraints
3 PARP Inhibitors for Cancer Market by Manufacturers
  1. 3.1 Global PARP Inhibitors for Cancer Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PARP Inhibitors for Cancer Sales by Manufacturers (2021-2026)
  3. 3.3 Global PARP Inhibitors for Cancer Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PARP Inhibitors for Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PARP Inhibitors for Cancer Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PARP Inhibitors for Cancer Manufacturers, Product Type & Application
  7. 3.7 Global PARP Inhibitors for Cancer Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PARP Inhibitors for Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PARP Inhibitors for Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PARP Inhibitors for Cancer Tier 1, Tier 2, and Tier 3
4 PARP Inhibitors for Cancer Market by Type
  1. 4.1 PARP Inhibitors for Cancer Type Introduction
  2. 4.1.1 Lynparza
  3. 4.1.2 Rubraca
  4. 4.1.3 Zejula
  5. 4.1.4 Talzenna
  6. 4.1.5 Other
  7. 4.2 Global PARP Inhibitors for Cancer Sales by Type
  8. 4.2.1 Global PARP Inhibitors for Cancer Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global PARP Inhibitors for Cancer Sales by Type (2021-2032)
  10. 4.2.3 Global PARP Inhibitors for Cancer Sales Market Share by Type (2021-2032)
  11. 4.3 Global PARP Inhibitors for Cancer Revenue by Type
  12. 4.3.1 Global PARP Inhibitors for Cancer Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global PARP Inhibitors for Cancer Revenue by Type (2021-2032)
  14. 4.3.3 Global PARP Inhibitors for Cancer Revenue Market Share by Type (2021-2032)
5 PARP Inhibitors for Cancer Market by Application
  1. 5.1 PARP Inhibitors for Cancer Application Introduction
  2. 5.1.1 Ovarian Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Other
  5. 5.2 Global PARP Inhibitors for Cancer Sales by Application
  6. 5.2.1 Global PARP Inhibitors for Cancer Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PARP Inhibitors for Cancer Sales by Application (2021-2032)
  8. 5.2.3 Global PARP Inhibitors for Cancer Sales Market Share by Application (2021-2032)
  9. 5.3 Global PARP Inhibitors for Cancer Revenue by Application
  10. 5.3.1 Global PARP Inhibitors for Cancer Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PARP Inhibitors for Cancer Revenue by Application (2021-2032)
  12. 5.3.3 Global PARP Inhibitors for Cancer Revenue Market Share by Application (2021-2032)
6 Global PARP Inhibitors for Cancer Sales by Region
  1. 6.1 Global PARP Inhibitors for Cancer Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PARP Inhibitors for Cancer Sales by Region (2021-2032)
  3. 6.2.1 Global PARP Inhibitors for Cancer Sales by Region (2021-2026)
  4. 6.2.2 Global PARP Inhibitors for Cancer Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PARP Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PARP Inhibitors for Cancer Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PARP Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PARP Inhibitors for Cancer Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PARP Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PARP Inhibitors for Cancer Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PARP Inhibitors for Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PARP Inhibitors for Cancer Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PARP Inhibitors for Cancer Revenue by Region
  1. 7.1 Global PARP Inhibitors for Cancer Revenue by Region
  2. 7.1.1 Global PARP Inhibitors for Cancer Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PARP Inhibitors for Cancer Revenue by Region (2021-2026)
  4. 7.1.3 Global PARP Inhibitors for Cancer Revenue by Region (2027-2032)
  5. 7.1.4 Global PARP Inhibitors for Cancer Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PARP Inhibitors for Cancer Revenue (2021-2032)
  8. 7.2.2 North America PARP Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PARP Inhibitors for Cancer Revenue (2021-2032)
  11. 7.3.2 Europe PARP Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PARP Inhibitors for Cancer Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PARP Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PARP Inhibitors for Cancer Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PARP Inhibitors for Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co
  2. 8.1.1 Merck & Co Company Information
  3. 8.1.2 Merck & Co Business Overview
  4. 8.1.3 Merck & Co PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co PARP Inhibitors for Cancer Product Portfolio
  6. 8.1.5 Merck & Co Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer PARP Inhibitors for Cancer Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca PARP Inhibitors for Cancer Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 Tesaro
  20. 8.4.1 Tesaro Company Information
  21. 8.4.2 Tesaro Business Overview
  22. 8.4.3 Tesaro PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tesaro PARP Inhibitors for Cancer Product Portfolio
  24. 8.4.5 Tesaro Recent Developments
  25. 8.5 Clovis Oncology
  26. 8.5.1 Clovis Oncology Company Information
  27. 8.5.2 Clovis Oncology Business Overview
  28. 8.5.3 Clovis Oncology PARP Inhibitors for Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Clovis Oncology PARP Inhibitors for Cancer Product Portfolio
  30. 8.5.5 Clovis Oncology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PARP Inhibitors for Cancer Value Chain Analysis
  2. 9.1.1 PARP Inhibitors for Cancer Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PARP Inhibitors for Cancer Production Mode & Process
  6. 9.2 PARP Inhibitors for Cancer Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PARP Inhibitors for Cancer Distributors
  9. 9.2.3 PARP Inhibitors for Cancer Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst